These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 1963545)

  • 1. Phase II study of high-dose epirubicin in non-small cell lung cancer.
    Wils J; Utama I; Sala L; Smeets J; Riva A
    Eur J Cancer; 1990; 26(11-12):1140-1. PubMed ID: 1963545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I-II study of high-dose epirubicin in advanced non-small-cell lung cancer.
    Feld R; Wierzbicki R; Walde PL; Shepherd FA; Evans WK; Gupta S; Shannon P; Lassus M
    J Clin Oncol; 1992 Feb; 10(2):297-303. PubMed ID: 1310105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of ifosfamide plus high-dose epirubicin in advanced non-small-cell lung cancer.
    Gridelli C; Rossi A; Incoronato P; Bruni GS; Scognamiglio F; Ruffolo P; Rinaldi L; Bianco AR
    Cancer Chemother Pharmacol; 1996; 37(6):613-5. PubMed ID: 8612318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic re-evaluation and phase I study of high dose epirubicin in advanced non-small cell lung cancer.
    Nishio M; Ohata M; Kobayashi H; Suruda T; Uetani K; Funasako M; Nishio K; Sasaki Y; Saijo N
    Jpn J Clin Oncol; 1993 Oct; 23(5):284-90. PubMed ID: 8230753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose epirubicin for untreated patients with advanced tumours: a phase I study.
    Martoni A; Melotti B; Guaraldi M; Pacciarini MA; Riva A; Pannuti F
    Eur J Cancer; 1990; 26(11-12):1137-40. PubMed ID: 1963544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 4'-EPI-doxorubicin in advanced lung cancer. A phase II trial.
    Giaccone G; Donadio M; Bonardi G; Iberti V; Calciati A
    Invest New Drugs; 1990 Nov; 8(4):393-6. PubMed ID: 1964677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epirubicin in patients with inoperable non-small cell lung cancer--a phase II study.
    Niiranen A; Kajanti M; Mattson K; Pyrhönen S
    Acta Oncol; 1991; 30(7):869-70. PubMed ID: 1662526
    [No Abstract]   [Full Text] [Related]  

  • 8. Accelerated cisplatin and high-dose epirubicin with G-CSF support in patients with relapsed non-small-cell lung cancer: feasibility and efficacy.
    Huisman C; Biesma B; Postmus PE; Giaccone G; Schramel FM; Smit EF
    Br J Cancer; 2001 Nov; 85(10):1456-61. PubMed ID: 11720428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of high-dose epirubicin and etoposide in advanced non-small cell lung cancer.
    Smit EF; Piers DA; Postmus PE
    Eur J Cancer; 1992; 28A(12):1965-7. PubMed ID: 1329882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epirubicin in previously untreated patients with small cell lung cancer: a phase II study by the EORTC Lung Cancer Cooperative Group.
    Quoix EA; Giaccone G; Jassem J; Karnicka H; Wiatr E; Cortes-Funes H; Roozendaal KJ; Kirkpatrick A; Evrard D; van Zandwijk N
    Eur J Cancer; 1992; 28A(10):1667-70. PubMed ID: 1327019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of high-dose epirubicin in advanced non-small cell lung cancer.
    Martoni A; Melotti B; Guaraldi M; Pannuti F
    Eur J Cancer; 1991; 27(10):1231-4. PubMed ID: 1659841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of epirubicin plus vinorelbine with or without G-CSF in advanced non-small cell lung cancer.
    Gridelli C; De Placido S; Pepe R; Incoronato P; Airoma G; Rossi A; Palazzolo G; Bianco AR
    Eur J Cancer; 1993; 29A(12):1729-31. PubMed ID: 7691117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of high dose epirubicin in unresectable non small cell lung cancer.
    Smit EF; Berendsen HH; Piers DA; Smeets J; Riva A; Postmus PE
    Br J Cancer; 1992 Mar; 65(3):405-8. PubMed ID: 1313691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study of high-dose epirubicin and vinorelbine in previously untreated non-small-cell lung cancer stage IIIB-IV.
    Bakker M; Groen HJ; Smit EF; Smeets J; Riggi M; Postmus PE
    Br J Cancer; 1995 Dec; 72(6):1547-50. PubMed ID: 8519675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and Paclitaxel as first-line treatment.
    Yang CH; Chen MC; Cheng AL; Hsu CH; Yeh KH; Yu YC; Whang-Peng J; Yang PC
    Oncology; 2005; 68(4-6):350-5. PubMed ID: 16020962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epirubicin: a phase II study in recurrent small-cell lung cancer.
    Rosenthal M; Kefford R; Raghavan D; Stuart-Harris R
    Cancer Chemother Pharmacol; 1991; 28(3):220-2. PubMed ID: 1713130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population-based phase I trial of irinotecan and epirubicin.
    Lau D; Johl J; Huynh M; Davies A; Tanaka M; Lara P; Gandara D
    Am J Clin Oncol; 2008 Jun; 31(3):226-30. PubMed ID: 18525299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II studies on weekly cisplatinum plus epirubicin or etoposide in the treatment of advanced non-small cell bronchogenic carcinoma.
    Lelli G; Casadio M; Giuliotti C; Giordani S; Martoni A; Strocchi E; Pannuti F
    Chemioterapia; 1986 Aug; 5(4):228-31. PubMed ID: 3021346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High dose epirubicin chemotherapy in untreated poorer prognosis small cell lung cancer.
    Banham SW; Henderson AF; Bicknell S; Hughes J; Milroy R; Monie RD
    Respir Med; 1990 May; 84(3):241-4. PubMed ID: 2171052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ifosfamide-based chemotherapy for previously treated lung cancer patients.
    Chen YM; Liu JM; Wu MF; Wu HW; Lin WC; Tsai CM; Perng RP; Whang-Peng J
    Zhonghua Yi Xue Za Zhi (Taipei); 1998 Jul; 61(7):389-96. PubMed ID: 9699391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.